Effects of CYP2C19 and MDR1 Genotype On the Eradication Rate of Helicobacter pylori Infection By PPI Based Triple Therapy

被引：0
|
作者：
Oh, Jung Hwan
Choi, Myung-Gyu
Dong, Mi Sook
Cho, Yu Kyung
Park, Jae Myung
Jeong, Jeong Jo
Lee, In Seok
Kim, Sang Woo
Chung, In-sik
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A342 / A342
页数：1
相关论文
共 50 条
  • [21] The effects of probiotics on the PPI triple therapy for Helicobacter pylori eradication
    Kim, M.
    Kim, N.
    Lee, D.
    Jung, H.
    Song, I.
    HELICOBACTER, 2007, 12 (04) : 437 - 437
  • [22] Effect of genetic polymorphism of CYP2C19 on eradication of Helicobacter pylori with various triple therapies
    Yamaji, Y
    Hirata, Y
    Akanuma, M
    Mitsuno, Y
    Maeda, S
    Ogura, K
    Okamoto, M
    Yoshida, H
    Kawabe, T
    Shiratori, Y
    Omata, M
    GASTROENTEROLOGY, 2001, 120 (05) : A587 - A587
  • [23] The effect of MDR1 C3435T polymorphism on the eradication rate of H. pylori infection in PPI-based triple therapy A meta-analysis
    Li, Meng
    Li, Taijie
    Guo, Shihui
    Liang, Hongjie
    Jiang, Dunke
    MEDICINE, 2017, 96 (13)
  • [24] Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage
    Kang, Jung Mook
    Kim, Nayoung
    Lee, Dong Ho
    Park, Young Soo
    Kim, Joo Sung
    Chang, In Jin
    Song, In Sung
    Jung, Hyun Chae
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (08) : 1287 - 1291
  • [25] Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β
    Bakulina, N., V
    Maev, I., V
    Savilova, I., V
    Bakulin, I. G.
    Il'chishina, T. A.
    Zagorodnikova, K. A.
    Murzina, A. A.
    Andreev, D. N.
    TERAPEVTICHESKII ARKHIV, 2019, 91 (08) : 34 - 40
  • [26] Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype
    Inaba, T
    Mizuno, M
    Kawai, K
    Yokota, K
    Oguma, K
    Miyoshi, M
    Take, S
    Okada, H
    Tsuji, T
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (07) : 748 - 753
  • [27] Famotidine increases the cure rates of Helicobacter pylori infection by a triple therapy in patients with the homozygous extensive metabolizer genotype of CYP2C19
    Okudaira, K
    Furuta, T
    Shirai, N
    Miura, S
    GASTROENTEROLOGY, 2004, 126 (04) : A188 - A188
  • [28] Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication
    Ozdil, Burhan
    Akkiz, Hikmet
    Bayram, Suleyman
    Bekar, Aynur
    Akgollu, Ersin
    Sandikci, Macit
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2010, 21 (01): : 23 - 28
  • [29] The efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism
    Chen, MC
    Hu, CT
    Wang, LY
    Lin, HH
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (03) : 274 - 275
  • [30] Influence of CYP2C19 polymorphism and helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection
    Furuta, T
    Sagehashi, Y
    Shirao, N
    Sugimoto, M
    Nakamura, A
    Kodaira, M
    Kenmotsu, K
    Nagano, M
    Egashira, T
    Ueda, K
    Yoneyama, M
    Ohashi, K
    Ishizaki, T
    Hishida, A
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2005, 3 (06) : 564 - 573
12345